FY2025 EPS Estimates for BCAX Reduced by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has revised its FY2025 earnings per share estimate for Bicara Therapeutics from ($2.11) to ($2.19), indicating a weaker outlook.
• Other analysts have issued mixed ratings and adjusted price targets for Bicara, with HC Wainwright lowering its target from $44.00 to $41.00 while Wells Fargo upgraded its rating to "equal weight" with a price target of $8.00.
• Bicara's stock holds an average rating of "Moderate Buy" with a consensus price target of $31.86 and has seen significant trading activity among institutional investors, including a 2,351% increase in Bank of America’s stake.

Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) - Equities research analysts at Cantor Fitzgerald lowered their FY2025 earnings per share (EPS) estimates for shares of Bicara Therapeutics in a research note issued to investors on Wednesday, August 13th. Cantor Fitzgerald analyst E. Schmidt now anticipates that the company will post earnings of ($2.19) per share for the year, down from their prior estimate of ($2.11). The consensus estimate for Bicara Therapeutics' current full-year earnings is ($2.59) per share. Cantor Fitzgerald also issued estimates for Bicara Therapeutics' FY2026 earnings at ($1.96) EPS.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.50) earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.04.

A number of other equities analysts also recently issued reports on the stock. Wells Fargo & Company raised shares of Bicara Therapeutics from an "underweight" rating to an "equal weight" rating and set a $8.00 price objective on the stock in a report on Friday, May 23rd. Wall Street Zen cut shares of Bicara Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Wedbush reaffirmed an "outperform" rating and issued a $30.00 price objective on shares of Bicara Therapeutics in a research report on Tuesday, August 12th. HC Wainwright decreased their price objective on shares of Bicara Therapeutics from $44.00 to $41.00 and set a "buy" rating for the company in a research note on Friday, May 16th. Finally, Piper Sandler started coverage on Bicara Therapeutics in a research note on Monday. They issued an "overweight" rating on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $31.86.

Bicara Therapeutics Stock Down 1.5%

NASDAQ BCAX traded down $0.17 on Friday, reaching $11.47. The company had a trading volume of 172,846 shares, compared to its average volume of 291,183. The company's fifty day moving average is $10.43 and its 200 day moving average is $11.93. Bicara Therapeutics has a 52-week low of $7.80 and a 52-week high of $28.09. The stock has a market capitalization of $625.80 million and a P/E ratio of -3.62.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System purchased a new stake in shares of Bicara Therapeutics during the 4th quarter worth approximately $25,000. CWM LLC bought a new position in Bicara Therapeutics during the first quarter valued at $29,000. Legal & General Group Plc increased its position in Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company's stock worth $29,000 after buying an additional 1,233 shares during the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Bicara Therapeutics in the fourth quarter valued at $32,000. Finally, Ameritas Investment Partners Inc. lifted its position in shares of Bicara Therapeutics by 73.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company's stock valued at $32,000 after buying an additional 1,474 shares during the last quarter.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.